GeneTrove provides complete solutions for determining the function of human genes and their usefulness as drug targets. Our offering includes Custom Gene Functionalization and Target Validation collaborations, the only Human Gene Function Database, and licenses to our comprehensive and dominating antisense target validation IP portfolio. Custom Target Validation: Isis has over 12 years experience in applying antisense technology for both functional genomics and drug discovery. GeneTrove gives you access to that expertise by providing validated antisense inhibitors for use in both cell culture and animal models of disease. These collaborations provide: 1) Most potent, longest acting, least toxic, best characterized inhibitors 2) Fastest path from gene sequence to gene function and target validation 3) Most cost-effective means from gene sequence to gene function and target validation Patent Licenses: GeneTrove offers access to the most comprehensive portfolio of intellectual property to enable customers to practice antisense technology for drug discovery research. This portfolio of issued and pending patents covers the most broadly utilized antisense chemistries, motifs and mechanisms of action (including methods to activate the RNase H enzyme to cause reduction of target RNA) for validating gene targets. Licenses to our patent portfolio ensure freedom to operate and access to the most favored business terms.
GenExel is a functional genomics company specializing in rapid disease gene target discovery and validation for drugs to treat a wide spectrum of human diseases. The Company utilizes the unmatched power of model organism genetics to select priority candidate drug targets from the sea of genomic information. GenExel has industrialized the world's largest and most comprehensive system to interrogate an animal genome and identify functionally relevant genes within human disease gene-associated networks, thus greatly accelerating the pace of rational drug design and development.
ImmPORT's revolutionary technology enables fast, comprehensive and high-throughput analysis of immune responses to infectious disease antigens. It is ideal for vaccine and diagnostics development or clinical analysis. A pre-printed array for simultaneous serological detection of multiple infectious agents is available in early 2007 (learn more about "PathogenChip"). The technology is also available as a custom whole proteome synthesis, micro-array fabrication and analysis service . The primary competitive benefits are: Much faster results: starting from gene sequences and genomic DNA, we express, array and screen all antigens in the proteome within weeks. . Much higher success rate : high efficiency cell free expression system with tolerance for toxic genes (> 95% of viral and bacterial genes have been successfully expressed). Much better sensitivity and dynamic range: suitable for serum screening assays with minute sample volumes and over a wide range of sample dilution. Reliable to use: built in controls (e.g. built in QC elements) to help eliminate false negatives and false positives. Much more economic: proprietary technology dramatically reduces the cost and time over conventional approaches. Analysis can be done using standard fluorescence or colorimetric assays. Highly Flexible: please contact us to inquire about pre-printed and custom arrays, e.g. entire proteomes or selected antigens/domains. Services include analyses of customer samples and array design.
Originus (www.originusinc.com) is a development stage drug research and discovery organization established to respond to the enormous opportunity that has been created by the completion of the sequencing of the human genome. Originus' mission is to revolutionize the discovery and development of pharmaceutical solutions to unmet medical needs by combining uniquely efficient, functional genomics and proteomics technologies with advanced cell biology techniques.
The CFG provides basic laboratory services to hundreds of bioscience researchers at companies, universities, and government agencies around the world, helping them create robust, reliable results quickly and affordably. We handle projects of any size, from single sample analyses to long-term work as collaborators or subcontractors on NIH grants. Each client is assigned a Ph.D.-level scientist to coordinate their project, meeting budget and deadline needs. CFG also has a strategic alliance with Commonwealth Biotechnologies, Inc. for projects that need to meet FDA requirements for submission of data in support of new drug applications. We are happy to participate on conference calls with prospective clients to determine how the CFG can best meet your needs. As part of its mission, the CFG maintains core competencies in genomics, proteomics, bioinformatics, transgenesis and cell and tissue culture.
Ribonomics provides a collaborative and team oriented work environment. If you are a self-starter and work well in an entrepreneurial atmosphere we want to hear from you! We currently do not have any job openings. However, we welcome qualified and motivated individuals to send their resumes for the following areas: Molecular Biologist Protein Chemist Manager, Business Development Laboratory Technician Director of Bioinformatics Bioinformatics Scientist Antibody Specialist Research Scientist Email resumes and cover letters to to ,,,,,,,,,,,,,,,,,,,. Ribonomics is located in Durham, NC near Research Triangle Park and Duke University. We are an equal opportunity employer, and provide competitive compensation and benefits.
In partnership with Genome Canada, Industry Canada and the Province of Alberta, Genome Alberta was established in the fall of 2005 to focus on genomics as one of the central components of the Life Sciences Initiative in Alberta, and to help position the Initiative as a core research effort similar to that developed for the provincial energy and information technology sectors. Within the next five years, Genome Alberta will be the leading source of information and administration related to genomics, proteomics, bioinformatics and bioethics research in Alberta. We are dedicated to informing students, researchers, research organizations, our partners, and the public regarding opportunities and challenges in genomics and proteomics, and in encouraging the development of a vibrant and vigorous Life Sciences research industry for the benefit of all Albertans. The opportunities arising from our genomics research and development activities will be communicated to high school, undergraduate and graduate students who are currently making career choices and who will be the future generations leading our evolving society when the applications and rewards of Life Sciences research become increasingly apparent. Genome Alberta will support our internationally acclaimed researchers who are engaged in world-class programs of investigation, exploration and discovery. We will provide them with the most sophisticated technologies to enable advances in fundamental genomics and proteomics in strategic priority areas. The discoveries and inventions arising from Genome Alberta research programs will be developed in partnership with provincial educational and research institutions, private industry, government agencies and departments, and with regional, national and international research teams and organizations that will ultimately realize social, economic, environmental and medical benefits for all Albertans and Canadians. As a new entity, focused on genomics research and technological advances emerging in Alberta , and in conjunction with our local, regional, national and international partners, Genome Alberta has ambitious goals. Supported by the prosperity of Alberta's economy, the high education levels of our mathematics and science students, the national and international ranking of our universities, technical schools and medical centers, and the internationally acclaimed accomplishments of our researchers and scientists, all funded by a host of institutional, industrial and government partners, Genome Alberta is confident that we will, within our 5-year mandate, help position Life Sciences research as a driving force for Alberta's future.
http://www.helicontherapeutics.com
Helicon Therapeutics, headquartered in San Diego, currently has six drug programs at various stages of development. Each drug is designed to modulate different aspects of memory formation from short-term memories, such as working memory and executive function, to the conversion of short-term memory to long-term memory.
http://www.discoverygenomics.net
Discovery Genomics, Inc. (DGI) was founded in 2000 and became operational in January 2002. DGI maintains exclusive rights to two breakthrough technologies that significantly enhance the development of new therapeutics - from gene discovery to treatment delivery. Our primary focus is to use these proprietary technologies to deliver gene therapies for blood diseases in collaboration with strategic partners. To advance our gene therapy development efforts, we also seek to license our technologies in areas outside our therapeutic focus.
Agritope is an Oregon-based agricultural functional genomics and biotechnology company that develops improved plant products and provides technology to the agricultural industry. Its fruit and vegetable division specializes in the development of improved fruit, vegetable and flower varieties. Agrinomics LLC, its 50%-owned joint venture with Aventis CropScience (NYSE: AVE), conducts a research, development and commercialization program in the field of plant functional genomics. Vinifera, Inc., its majority-owned subsidiary, offers superior grapevine plants to the premium wine industry together with disease testing and elimination services.
Senesco Technologies, Inc. is a development-stage company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing eucaryotic translation initiation Factor 5A and deoxyhypusine synthase (DHS), in human health applications to develop approaches to treat inflammatory and / apoptotic-related diseases in humans, approaches to treat cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants. On September 11, 2007 it entered into a license agreement with Bayer CropScience AG for the development and commercialization of rice. (Source: 10-K)
GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of ‘next generation' protein products for already-developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins.
Divergence, a world leader in the application of comparative and functional genomics to agriculture and infectious disease, is dedicated to the discovery of highly effective and ecologically sound strategies for parasite control. The Company's initial focus is on the critical unmet need to control plant, animal, and human parasitic nematodes (commonly referred to as roundworms). Nematodes are one of the major agricultural pests in the world, causing significant damage to dozens of major crops. Current nematicides are environmentally dangerous, expensive, and difficult to use. Nematodes are also major pathogens of humans, companion animals, and livestock causing a range of diseases including hookworm, lymphatic filariasis, and heartworm. Divergence's innovative discovery methods can also be applied to other pests, such as insects, and infectious disease-causing organisms including protozoan parasites and fungal pathogens. One of the major barriers to the discovery of new methods of parasite control has been discovering molecules that are selective for the infecting organism rather than general toxins. Achieving selectivity has been a particular challenge for eukaryotic and especially metazoan pathogens such as nematodes (roundworms) and arthropods (including insects). Despite millions of years of evolutionary separation, metazoan still have much of their cellular structures and core molecular machinery in common, including neuronal and muscular physiology and most characterized biochemical and signal transduction pathways. Most efficacious molecules to emerge from whole-organism screens in recent decades have exhibited cross-toxicity with the host or other non-target organisms. Divergence has developed a cutting-edge discovery platform in comparative and functional genomics that enables the accelerated identification and prioritization of molecular targets for parasite control. Divergence's proprietary target gene collection includes newly identified enzymes and receptors essential for nematode survival that are absent from humans and other non-target organisms. This strategy directs research away from molecules that could have host organism toxicity, focusing instead on targets that are pharmacologically distinct and vital for the life cycle of the infecting organism. This approach provides Divergence and its collaborators with an enormous advantage because it decreases the risk of late-stage project failure due to product safety or environmental issues and can potentially decrease the time and cost of regulatory studies. Divergence combines its innovative approaches to target selection and validation with state-of-the-art in house and collaborative programs in chemical lead identification through molecular expression, biochemistry, chemical synthesis and SAR (structure-activity-relationship) model development, in vitro and in vivo physiological screens, rapid in planta testing systems for parasite control, and toxicity testing, allowing the progression of lead molecules from test tube to field. Cost and time-effective systems have also been developed for in planta testing of transgenic parasite resistance traits. Divergence's experienced science professionals combine extensive expertise in both agrochemical and veterinary pharmacology product discovery and development with leading capabilities in the use of the genetic model system C. elegans. Divergence is exploring and implementing commercial partnerships with leading companies in crop protection and pharmaceuticals to rapidly commercialize products resulting from its research. The company leverages its research strengths through intellectual property positions which cover multiple compounds and delivery systems, multiple hosts, and multiple pathogens. Over 30 patents have been filed on gene sequences as well as nematicidal chemistries and transgenes resulting from discoveries using these targets. Divergence's business team has extensive experience in biotechnology licensing, product development, strategic planning with companies such as Monsanto and Fort Dodge, and its board of directors includes former leaders of two of the world's leading hybrid seed companies, Pioneer Hi-Bred and DeKalb Corporation. Divergence Inc. is part of the St. Louis BioBelt (http://www.biobelt.org/) a world-class center for plant and life sciences research, investment and business opportunity. The BioBelt is home to 390 plant and life sciences enterprises employing 22,000 and generating more than $10.5 billion in direct and indirect annual economic impact. Divergence Inc. collaborates with multiple St. Louis-based academic and commercial institutions including Washington University School of Medicine, the number 2 ranked medical school in the United States, the Donald Danforth Plant Science Center, a leading institute for plant biology working to increase agricultural production world-wide, and Tripos Inc., a pioneer in cheminformatics and supplier of chemistry-research products and services for the biotechnology and pharmaceutical industry. Above left: The nematode C. elegans, stained to show its DNA, is overlaid on the image of a fluorescent DNA sequencing gel.
Mendel Biotechnology was founded in early 1997 based on the idea that controlling gene expression would create new opportunities to improve plant productivity and quality. From 1997-2003, we focused on understanding the functions of a large class of genes called transcription factors, in the model plant Arabidopsis, because each transcription factor can regulate and coordinate the expression of a set of effector genes that together determine specific plant characteristics. Of the approximately 30,000 genes in the Arabidopsis genome nearly 2,000 are transcription factors. By systematically analyzing the function of all Arabidopsis transcription factors, Mendel scientists discovered individual transcription factors that control complex valuable traits such as freezing tolerance, drought tolerance, intrinsic growth rate, photosynthetic output, plant form, disease resistance, water use efficiency, nitrogen use efficiency and numerous other important processes. We have filed, and been granted, many patents protecting our inventions on the use of transcription factor-based technologies for improvement of plant traits. We believe that no other company or academic institution in the world has a comparable understanding of the function of transcription factors and that Mendel is the leading company in the world in this area. From 2003 to the present, through collaboration with our partners, a significant number of our transcription factor technologies have been shown to generate commercially meaningful improvements via genetic approaches in crops. Our inventions have been used to produce corn and soybean varieties with improved yield, drought-tolerant corn varieties, freezing-tolerant eucalyptus trees, and drought-tolerant ornamentals. We continue to work with several partners across a number of different market segments to create plants with improved yield and yield stability. In 2004, we began developing a novel application of our technology platforms and knowledge of plant transcription factor-regulated pathways: the discovery of compounds that could regulate valuable traits by direct chemical application to the plant. Starting again with the model species Arabidopsis, we identified molecules that improve tolerance to freezing, drought, and cold, and in so doing, validated this new chemistry platform. This has led to a collaboration with Bayer CropScience to identify commercially valuable chemistries that enhance stress tolerance, which we anticipate will create an entirely new agrochemical market. In 2005, we made a strategic decision to pursue biofuels as a new opportunity that we felt would grow significantly over the next decade. A mature global biofuels industry, as it progresses beyond initial approaches such as grain-derived ethanol, will require dedicated energy crops with high biomass yields, low inputs, and sustainable crop practices. Through a collaboration with BP, a leading company in alternative energy, we have begun to deploy both our chemistry and genetics platforms, in combination with conventional and marker-assisted breeding, to create elite, proprietary varieties of energy grasses. As such, Mendel is now creating a BioEnergy Seeds and Feedstocks business that will provide seeds and services to farmers, and refineries, for a second generation biofuels market, based around cellulosic feedstocks, that we envision will become a very large future industry.
ChondroGene Limited is a molecular diagnostics company that is developing proprietary blood-based molecular diagnostic tests for diseases with unmet clinical needs and significant commercial opportunities. The tests are based on the Company's breakthrough Sentinel Principle and are being developed in the areas of cancer, central nervous system disorders, cardiovascular diseases and arthritis with the initial focus for commercialization in cancer. To develop these tests, ChondroGene is applying the Sentinel Principle to generate molecular signatures from blood. These molecular signatures are used to identify disease-specific biomarkers which are the foundation for ChondroGene's highly sensitive and specific molecular diagnostic assays. ChondroGene is able to generate specific biomarkers in different disease areas for numerous applications including: Predicting disease risk Early diagnosis Determining stage of disease Identifying responders/non-responders to a specific therapy Monitoring progression/recurrence of disease Monitoring the effects of treatment Monitoring treatment compliance The broad applicability of the Sentinel Principle across a wide range of diseases and its ability to address a diverse spectrum of specific clinical questions means that it is truly a breakthrough technology with the ability to enable Personalized Health Management.
http://www.paradigm-therapeutics.com
Paradigm Therapeutics was founded in 1999 and has established world class target identification and validation capabilities based on gene knock out technology and in vivo pharmacology. The acquisition of Amedis Pharmaceuticals in January 2005 added key medicinal chemistry skills. The combined company has focused on the identification of novel, small molecule tractable targets with defined therapeutic utility within key gene families such as G-protein coupled receptors (GPCRs), ion channels and proteases. The company has developed a drug discovery pipeline comprising targets and late stage pre-clinical projects in key areas of unmet medical need in pain, CNS disorders, hormone dependent diseases such as prostate and breast cancer and metabolic diseases such as diabetes, hyperlipidemias, obesity and osteoporosis. In June 2005 Paradigm Therapeutics announced two major collaborations with Ortho-McNeil Pharmaceuticals (J&J) in pain and urinary urge incontinence and with Takeda in CNS disorders. The company is based in Cambridge UK and Singapore.
Interleukin Genetics, Inc. (Interleukin) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the personalized health market. The Company has two primary segments to its business. The first is a personalized health segment primarily focused on researching and developing genetic tests that target the role that genetically determined variations in the inflammatory response have on health and disease. The second segment, comprising the Interleukin brands consumer products business, focuses on developing, selling and marketing nutritional supplements and products into retail consumer channels. (Source: 10-K)
http://www.lexicon-genetics.com
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a diverse pipeline of drug targets behind its clinical programs with many compounds and antibodies in preclinical research. Lexicon is conducting clinical trials for four drug candidates, with its most advanced program in Phase II clinical trials.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory